In this presentation, Anand A. Patel, MD, reviewed the contemporary standard-of-care treatment roadmap for AML in 2025, covering key phases like induction chemotherapy (eg, the “7+3” regimen), consolidation…
Eunice S. Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, New York, discusses the treatment strategies for patients who develop secondary acute myeloid leukemia (AML) following hypomethylating agent…
The recent PLCO study and its results have sparked controversy in some circles. The trial concludes that routine PSA exams and digital rectal exams, standard screening exams for prostate cancer,…
NEW YORK (Reuters Health) – In a Korean study of patients with advanced non-small-cell lung cancer who had never smoked and were previously treated with platinum-based chemotherapy, progression-free…
NEW YORK (Reuters Health) – In a phase three study of elderly patients with newly diagnosed acute myeloid leukemia (AML), decitabine achieved a higher response rate, with a…
NEW YORK (Reuters Health) – Blood from patients with uncomplicated hemochromatosis is safe and effective for transfusion, researchers from the Belgian Red Cross report in the June 1st…
NEW YORK (Reuters Health) – A strategy that combines cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) provides acceptable long term survival for patients with pseudomyxoma peritonei of appendiceal…
NEW YORK (Reuters Health) – Recombinant factor VIIa (rFVIIa) appears to be safe and effective when used for off-label indications in pediatric patients, according to a report from…
NEW YORK (Reuters Health) – Compared to white light cystoscopy, hexaminolevulinate fluorescence cystoscopic detection of papillary, nonmuscle invasive bladder cancer appears superior, researchers report in a May 12th…
NEW YORK (Reuters Health) – Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a good first test in patients with isolated mediastinal lymphadenopathy (IML), one that might spare many…
NEW YORK (Reuters Health) – In real-world patients with diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma (NHL), adding rituximab to first-line chemotherapy improves…
NEW YORK (Reuters Health) – Patients treated in childhood for Hodgkin lymphoma or Wilms tumor are at particularly high risk for developing colorectal cancer at a relatively young…
